A股異動 | 光智科技漲7% 研製出13N超高純鍺單晶 項目取得歷史性突破
格隆匯11月25日丨光智科技(300489.SZ)現漲7.53%,報30.27元,總市值41億元。11月24日,據廣東先導稀材公司官微消息,近日,安徽光智科技有限公司(簡稱“光智科技”)成功研製出13N(即99.99999999999%)超高純鍺單晶,突破了國外長期對超高純鍺的封鎖和壟斷。目前,光智科技擁有全自動單晶生長爐等先進的研發設備,掌握了超高純鍺單晶製備的關鍵技術,解決了卡脖子問題,填補了國內該領域的空白,並已建成具有國際先進水平的超高純鍺生產線,可為全球客户供應高質量的13N超高純鍺單晶。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.